ACQUITY™ UPLC™ I-Class/Xevo™ TQ Absolute IVD system: Analytical performance for immunosuppressive agents

This is an Application Brief and does not contain a detailed Experimental section.

For in vitro diagnostic use. Not available in all countries.

The ACQUITY™ UPLC™ I-Class/Xevo™ TQ Absolute IVD System from Waters is designed to facilitate the accurate quantification of organic compounds in human biological liquid matrices.

This document describes a test of the analytical performance of the ACQUITY UPLC I-Class/Xevo TQ Absolute IVD System for the analysis of cyclosporine, everolimus, sirolimus, and tacrolimus in whole blood.

Experimental

This work saw the ACQUITY UPLC I-Class/Xevo TQ Absolute IVD System controlled by MassLynx™ IVD (v4.2); data processing was acquired using the TargetLynx™ Application Manager. Whole blood Quality Controls and calibrators were processed according to the conditions outlined here.

Sample preparation conditions

A 50 µL sample was processed with acetonitrile and zinc sulfate before being centrifuged.

LS conditions

Source: Waters Advanced Diagnostics

. .
Column ACQUITY UPLC HSS C18 SB 1.8 µm, 2.1 mm x 30 mm,
Mobile phase A 2 mM Ammonium acetate + 0.1 % formic acid in water
Mobile phase B 2 mM Ammonium acetate + 0.1 % formic acid in methanol
Flow rate 0.4 mL/min
Gradient 50 % B for 0.2 minutes, 50–100 % B over 0.4 minutes, hold 100 % B for 0.6 minutes, equilibrate with 50 % B for 0.6 minutes at 0.6 mL/min

 

MS conditions

Source: Waters Advanced Diagnostics

. .
Resolution MS1 (0.75 FWHM), MS2 (0.75 FWHM)
Acquisition mode MRM
Polarity ESI+

 

Results and discussion

Table 1 features the performance characteristics of everolimus, sirolimus, cyclosporine, and tacrolimus on the ACQUITY UPLC I-Class/Xevo TQ Absolute IVD System, while Figure 1 illustrates the chromatographic separation’s analytical sensitivity.

Table 1. Performance characteristics of cyclosporine, everolimus, sirolimus, and tacrolimus. Range defined by linear fit where r2 >0.995. LLOQ defined by S/N (PtP) >10. Total precision and repeatability of QCs performed over five occasions in whole blood (n=25). EQA mean bias determined by comparison of obtained values to the LC-MS all laboratories trimmed mean (LC-MS ALTM) values (n=27 for cyclosporine, n=25 for everolimus, n=28 for sirolimus, and n=27 for tacrolimus). Source: Waters Advanced Diagnostics

Performance characteristics of cyclosporine, everolimus, sirolimus, and tacrolimus.

Chromatogram showing the analysis of 25 ng/mL cyclosporine and 1 ng/mL everolimus, sirolimus and tacrolimus using the ACQUITY UPLC I-Class/Xevo TQ Absolute IVD System

Figure 1. Chromatogram showing the analysis of 25 ng/mL cyclosporine and 1 ng/mL everolimus, sirolimus and tacrolimus using the ACQUITY UPLC I-Class/Xevo TQ Absolute IVD System. Image Credit: Waters Advanced Diagnostics

Conclusion

The Waters ACQUITY UPLC I-Class/Xevo TQD IVD System has demonstrated the capability to deliver analytical sensitivity, accuracy, and precision for the analysis of cyclosporine, everolimus, sirolimus, and tacrolimus in whole blood.

Disclaimer

The analytical performance data presented here is for illustrative purposes only. Waters does not recommend or suggest analysis of the analytes described herein. These data are intended solely to demonstrate the performance capabilities of the system for analytes representative of those commonly analyzed using liquid chromatography and tandem mass spectrometry. Performance in an individual laboratory may differ due to a number of factors, including laboratory methods, materials used, intra-operator technique, and system conditions. This document does not constitute a warranty of merchantability or fitness for any particular purpose, express or implied, including for the testing of the analytes in this analysis.

Acknowledgments

Produced from materials originally authored by Stephen Balloch, Gareth Hammond, and Elizabeth Embrey from Waters Corporation.

About Waters Advanced Diagnostics

At Waters, we recognize the critical role hospital laboratories play in delivering timely, accurate diagnostics that drive patient care. Our solutions are built to support your lab’s evolving needs - whether you’re expanding test menus, improving turnaround times, or meeting rigorous regulatory standards.

Rooted in three foundational pillars, our approach is designed specifically for clinical lab environments like yours:

Flexibility – Integrate seamlessly into your existing systems and workflows.

Efficiency – Help your team deliver high-quality results faster and with fewer hands-on steps.

Trust – Proven technologies backed by decades of scientific innovation and global support.

From LC-MS/MS systems to automated sample preparation and data management tools, Waters offers comprehensive solutions that enable your lab to operate with confidence - today and in the future.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Nov 12, 2026 at 7:50 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Waters Advanced Diagnostics. (2026, November 12). ACQUITY™ UPLC™ I-Class/Xevo™ TQ Absolute IVD system: Analytical performance for immunosuppressive agents. News-Medical. Retrieved on November 12, 2026 from https://www.news-medical.net/whitepaper/20261112/ACQUITYe284a2-UPLCe284a2-I-ClassXevoe284a2-TQ-Absolute-IVD-system-Analytical-performance-for-immunosuppressive-agents.aspx.

  • MLA

    Waters Advanced Diagnostics. "ACQUITY™ UPLC™ I-Class/Xevo™ TQ Absolute IVD system: Analytical performance for immunosuppressive agents". News-Medical. 12 November 2026. <https://www.news-medical.net/whitepaper/20261112/ACQUITYe284a2-UPLCe284a2-I-ClassXevoe284a2-TQ-Absolute-IVD-system-Analytical-performance-for-immunosuppressive-agents.aspx>.

  • Chicago

    Waters Advanced Diagnostics. "ACQUITY™ UPLC™ I-Class/Xevo™ TQ Absolute IVD system: Analytical performance for immunosuppressive agents". News-Medical. https://www.news-medical.net/whitepaper/20261112/ACQUITYe284a2-UPLCe284a2-I-ClassXevoe284a2-TQ-Absolute-IVD-system-Analytical-performance-for-immunosuppressive-agents.aspx. (accessed November 12, 2026).

  • Harvard

    Waters Advanced Diagnostics. 2026. ACQUITY™ UPLC™ I-Class/Xevo™ TQ Absolute IVD system: Analytical performance for immunosuppressive agents. News-Medical, viewed 12 November 2026, https://www.news-medical.net/whitepaper/20261112/ACQUITYe284a2-UPLCe284a2-I-ClassXevoe284a2-TQ-Absolute-IVD-system-Analytical-performance-for-immunosuppressive-agents.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.